| Patient ID | Sex | Diagnosis | Age | Tumor Stage | Tumor grade | Disease Status | Relapse Type | Survival Status | Survival Time | Missense Mutation - KRAS | Missense Mutation - TP53 | Missense Mutation - CDKN2A | Missense Mutation - SMAD4 | hidden | hidden | hidden | hidden |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DO46744 | Male | PNET | 69 | T2N0MX | G1 | Stable | NA | Alive | 1916.0 | No | No | No | No | 6.0 | No | No | DO46744 |
| DO46745 | Male | PNET | 48 | T2N0MX | G1 | Stable | NA | Alive | 1803.0 | No | No | No | No | 5.0 | No | No | DO46745 |
| DO46747 | Male | PNET | 74 | T2N0MX | G1 | Stable | NA | Deceased | 102.0 | No | No | No | No | 1.0 | No | No | DO46747 |
| DO46749 | Male | PNET | 78 | T2N1MX | G1 | Stable | NA | Alive | 1379.0 | No | No | No | No | 4.0 | No | No | DO46749 |
| DO46751 | Male | PNET | 76 | T3N1MX | G1 | Progression | Distant recurrence/metastasis | Deceased | 600.0 | No | No | No | No | 2.0 | No | No | DO46751 |
| DO46753 | Female | PNET | 59 | T3N0MX | G1 | Stable | NA | Alive | 1173.0 | No | No | No | No | 4.0 | No | No | DO46753 |
| DO46755 | Male | PNET | 59 | T3N0MX | G1 | Stable | NA | Deceased | 25.0 | No | No | No | No | 1.0 | No | No | DO46755 |
| DO46757 | Male | PNET | 66 | T3N1MX | G1 | Stable | NA | Alive | 503.0 | No | No | No | No | 2.0 | No | No | DO46757 |
| DO46759 | Male | PNET | 61 | T3N1MX | G1 | Progression | Distant recurrence/metastasis | Alive | 903.0 | No | No | No | No | 3.0 | No | No | DO46759 |
| DO46761 | Female | PNET | 67 | T2NXMX | G1 | Stable | NA | Alive | 764.0 | No | No | No | No | 3.0 | No | No | DO46761 |
| DO46763 | Male | PNET | 79 | IV | G1 | Progression | Distant recurrence/metastasis | Alive | 870.0 | No | No | No | No | 3.0 | No | No | DO46763 |
| DO46765 | Female | PNET | 38 | T3N1MX | G1 | Progression | Distant recurrence/metastasis | Alive | 779.0 | No | No | No | No | 3.0 | No | No | DO46765 |
| DO46767 | Female | PNET | 65 | T2N0MX | G1 | Stable | NA | Alive | 608.0 | No | No | No | No | 2.0 | No | No | DO46767 |
| DO46769 | Female | PNET | 69 | T2N0MX | G1 | Stable | NA | Alive | 638.0 | No | No | No | No | 2.0 | No | No | DO46769 |
| DO46771 | Female | PNET | 45 | T2N0MX | G1 | Stable | NA | Alive | 652.0 | No | No | No | No | 2.0 | No | No | DO46771 |
| DO46773 | Female | PNET | 44 | T1N0MX | G1 | Stable | NA | Alive | 576.0 | No | No | No | No | 2.0 | No | No | DO46773 |
| DO46777 | Male | PNET | 81 | T1N0MX | G1 | Stable | NA | Alive | 453.0 | No | No | No | No | 2.0 | No | No | DO46777 |
| DO46779 | Male | PNET | 77 | T3N0MX | G1 | Stable | NA | Alive | 437.0 | No | No | No | No | 2.0 | No | No | DO46779 |
| DO46781 | Male | PNET | 56 | T2N0MX | G1 | Stable | NA | Alive | 328.0 | No | No | No | No | 1.0 | No | No | DO46781 |
| DO46783 | Male | PNET | 78 | T3N1MX | G3 | Stable | NA | Alive | 350.0 | No | No | P72L,P113L | No | 1.0 | No | No | DO46783 |
| DO46785 | Male | PNET | 59 | T2N0MX | G1 | Progression | Distant recurrence/metastasis | Alive | 392.0 | No | No | No | No | 2.0 | No | No | DO46785 |
| DO48503 | Female | PNET | 35 | T1NXMX | G1 | Stable | NA | Alive | 1816.0 | No | No | No | No | 5.0 | No | No | DO48503 |
| DO48506 | Female | PNET | 47 | T1N0MX | G1 | Progression | Local recurrence | Deceased | 1222.0 | No | No | No | No | 4.0 | No | No | DO48506 |
| DO48510 | Female | PNET | 53 | T2N1MX | G1 | Stable | NA | Alive | 1332.0 | No | No | No | No | 4.0 | No | No | DO48510 |
| DO48519 | Male | PNET | 41 | T3N0MX | G1 | Stable | NA | Alive | 901.0 | No | No | No | No | 3.0 | No | No | DO48519 |
| DO48520 | Female | PNET | 59 | T2N0MX | G1 | Stable | NA | Alive | 537.0 | No | No | No | No | 2.0 | No | No | DO48520 |
| DO48522 | Female | PNET | 51 | T3N0MX | G1 | Stable | NA | Alive | 926.0 | No | No | No | No | 3.0 | No | No | DO48522 |
| DO48526 | Male | Carcinoma, NOS | 36 | NA | NA | Progression | Distant recurrence/metastasis | Alive | 6360.0 | No | No | No | No | 18.0 | No | No | DO48526 |
| DO48530 | Male | PNET | 33 | IIA | G1 | Stable | NA | Alive | 405.0 | No | No | No | No | 2.0 | No | No | DO48530 |
| DO48531 | Female | PNET | 65 | T2N0MX | G2 | Stable | NA | Alive | 312.0 | No | No | No | No | 1.0 | No | No | DO48531 |
| DO48536 | Female | PNET | 72 | T4N1MX | G1 | Stable | NA | Alive | 217.0 | No | No | No | No | 1.0 | No | No | DO48536 |
| DO48539 | Male | PNET | 38 | IV | G3 | Progression | Local recurrence | Deceased | 209.0 | No | No | No | No | 1.0 | No | No | DO48539 |
| DO48541 | Male | PNET | 68 | T2N0MX | G1 | Stable | NA | Alive | 429.0 | No | No | No | No | 2.0 | No | No | DO48541 |
| DO48542 | Male | PNET | 71 | T1N0MX | G1 | Stable | NA | Alive | 280.0 | No | No | No | No | 1.0 | No | No | DO48542 |
| DO48545 | Male | PNET | 56 | T1N0MX | G1 | Stable | NA | Alive | 370.0 | No | No | No | No | 2.0 | No | No | DO48545 |
| DO48549 | Male | PNET | 40 | T3N1MX | G1 | Stable | NA | Alive | 385.0 | No | No | No | No | 2.0 | No | No | DO48549 |
| DO48553 | Male | PNET | 64 | T1N0MX | G1 | Stable | NA | Alive | 482.0 | No | No | No | No | 2.0 | No | No | DO48553 |
| DO48554 | Male | PNET | 38 | NA | G1 | Stable | NA | Alive | 275.0 | No | No | No | No | 1.0 | No | No | DO48554 |
| DO48557 | Male | PNET | 52 | T3N0MX | NA | Stable | NA | Alive | 227.0 | No | No | No | No | 1.0 | No | No | DO48557 |
| DO48560 | Male | PNET | 51 | T2N1MX | G1 | Stable | NA | Alive | 132.0 | No | No | No | No | 1.0 | No | No | DO48560 |
| DO48563 | Male | PNET | 55 | T3NXMX | G1 | Stable | NA | Alive | 229.0 | No | No | No | No | 1.0 | No | No | DO48563 |
| DO48564 | Female | PNET | 68 | T2N0MX | G2 | Stable | NA | Alive | 270.0 | No | No | No | No | 1.0 | No | No | DO48564 |
| DO48567 | Female | PNET | 61 | T3N0MX | G1 | Stable | NA | Alive | 19.0 | No | No | No | No | 1.0 | No | No | DO48567 |
| DO48570 | Female | PNET | 76 | T1N0MX | G1 | Stable | NA | Alive | 272.0 | No | No | No | No | 1.0 | No | No | DO48570 |
| DO48573 | Male | PNET | 71 | T3N1MX | G2 | Stable | NA | Alive | 242.0 | No | No | No | No | 1.0 | No | No | DO48573 |
| DO48574 | Female | PNET | 75 | T1N0MX | G1 | Stable | NA | Alive | 61.0 | No | No | No | No | 1.0 | No | No | DO48574 |
| DO48578 | Female | PNET | 59 | T2N1MX | G2 | Progression | NA | Alive | 7.0 | No | No | No | No | 1.0 | No | No | DO48578 |
| DO48580 | Female | PNET | 71 | T3N1MX | G2 | Stable | NA | Alive | 17.0 | No | No | No | No | 1.0 | No | No | DO48580 |
| DO48581 | Male | PNET | 64 | T3N0MX | G2 | Stable | NA | Alive | 40.0 | No | No | No | No | 1.0 | No | No | DO48581 |
| DO50305 | Female | Mixed ductal-endocrine carcinoma | 51 | IV | G2 | Progression | Distant recurrence/metastasis | Deceased | 548.0 | No | R248Q,R155Q,R116Q | No | No | 2.0 | No | Yes | DO50305 |
| DO51169 | Male | PNET | 35 | IV | G2 | Stable | NA | Alive | 708.0 | No | No | No | No | 2.0 | No | No | DO51169 |
| DO51170 | Male | PNET | 41 | IIB | G1 | Stable | NA | Alive | 3016.0 | No | No | No | No | 9.0 | No | No | DO51170 |
| DO51171 | Female | PNET | 74 | IIB | G2 | Stable | NA | Alive | 2943.0 | No | No | No | No | 9.0 | No | No | DO51171 |
| DO51172 | Male | PNET | 62 | IIB | G2 | Progression | Distant recurrence/metastasis | Alive | 2723.0 | No | No | No | No | 8.0 | No | No | DO51172 |
| DO51173 | Female | PNET | 39 | IA | G1 | Stable | NA | Alive | 1244.0 | No | No | No | No | 4.0 | No | No | DO51173 |
| DO51174 | Male | PNET | 63 | IB | G1 | Stable | NA | Alive | 1519.0 | No | No | No | No | 5.0 | No | No | DO51174 |
| DO51175 | Female | PNET | 71 | IA | G1 | Stable | NA | Deceased | 413.0 | No | No | No | No | 2.0 | No | No | DO51175 |
| DO51176 | Female | PNET | 64 | IV | G2 | Progression | Distant recurrence/metastasis | Alive | 1378.0 | No | No | No | No | 4.0 | No | No | DO51176 |
| DO51177 | Male | PNET | 36 | IIB | G2 | Stable | NA | Alive | 1072.0 | No | No | No | No | 3.0 | No | No | DO51177 |
| DO51178 | Male | PNET | 53 | IV | G1 | Progression | Distant recurrence/metastasis | Deceased | 121.0 | No | No | No | No | 1.0 | No | No | DO51178 |
| DO51179 | Male | PNET | 64 | IA | G1 | Stable | NA | Alive | 2456.0 | No | No | No | No | 7.0 | No | No | DO51179 |
| DO51180 | Male | PNET | 56 | IV | G2 | Stable | NA | Alive | NA | No | No | No | No | NA | No | No | DO51180 |
| DO51181 | Female | PNET | 26 | IV | G2 | Stable | NA | Alive | 2402.0 | No | No | No | No | 7.0 | No | No | DO51181 |
| DO51182 | Male | PNET | 50 | IV | G2 | Progression | Distant recurrence/metastasis | Deceased | 522.0 | No | No | No | No | 2.0 | No | No | DO51182 |
| DO51184 | Female | PNET | 34 | IIB | G2 | Stable | NA | Alive | 2345.0 | No | No | No | No | 7.0 | No | No | DO51184 |
| DO51185 | Male | PNET | 17 | IB | G1 | Stable | NA | Alive | NA | No | No | No | No | NA | No | No | DO51185 |
| DO51187 | Female | PNET | 69 | III | G2 | Progression | Distant recurrence/metastasis | Alive | 2318.0 | No | No | No | No | 7.0 | No | No | DO51187 |
Overview
Patient Statistics
Tumour Statistics
Cohort Summary
Variant Identification
Drug Prediction
Cancer Genome Interpreter (CGI) help
| Gene | Protein Alteration | Alteration Match | Drug | Effect | Tumour | Evidence |
|---|---|---|---|---|---|---|
| SETD2 | R2040* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | R2040* | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SF3B1 | K666E | Different Mutation | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| ALK | intron_variant | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | intron_variant | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | intron_variant | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | intron_variant | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | intron_variant | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| NTRK3 | intron_variant | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| ESR1 | intron_variant | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| AKT3 | intron_variant | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | intron_variant | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | intron_variant | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| EGFR | intron_variant), EGFR MUT* (intron_variant), EGFR MUT* (intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | intron_variant), EGFR MUT* (intron_variant), EGFR MUT* (intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| JAK2 | intron_variant | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| ROS1 | 5-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | 5-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | 5-UTRSNV | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | 5-UTRSNV | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | 5-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NOTCH2 | C148Y | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB4 | intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| SETD2 | Q854* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | Q854* | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| PDGFRA | intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| CRLF2 | intron_variant), CRLF2 MUT* (intron_variant | Different Alteration | MTOR inhibitor | Responsive | ALL | Pre-clinical |
| CRLF2 | intron_variant), CRLF2 MUT* (intron_variant | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| BCR | intron_variant | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | intron_variant | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | intron_variant | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | intron_variant | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | intron_variant | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| VHL | Q132* | Complete Match | VEGFR inhibitor | Responsive | R | Pre-clinical |
| ERBB4 | intron_variant), ERBB4 MUT* (IntronicBlockSubstitution), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PDGFB | intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| ROS1 | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | intron_variant | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| MET | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NOTCH2 | intron_variant | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | 5-UTRSNV), ALK MUT* (intron_variant | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| FGFR2 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| ESR1 | IntronicBlockSubstitution | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ESR1 | intron_variant), ESR1 MUT* (intron_variant | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| EGFR | intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PML | V803V | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | V803V | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | V803V | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| NOTCH1 | intron_variant), NOTCH1 MUT* (L2014L | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | intron_variant), NOTCH1 MUT* (L2014L | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| BRD4 | intron_variant | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PML | intron_variant | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | intron_variant | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | intron_variant | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| TP53 | R196* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R196* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R196* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R196* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R196* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R196* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R196* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R196* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R196* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R196* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R196* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R196* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R196* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R196* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R196* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDKN2A | R58* | Complete Match | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | R58* | Complete Match | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | R58* | Complete Match | CDK4/6 inhibitor | Responsive | CM | Case report |
| CDKN2A | R58* | Complete Match | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | R58* | Different Alteration | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | R58* | Different Alteration | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | R58* | Different Alteration | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | R58* | Different Alteration | CDK4/6 inhibitor | Responsive | CM | Case report |
| CRLF2 | intron_variant | Different Alteration | MTOR inhibitor | Responsive | ALL | Pre-clinical |
| CRLF2 | intron_variant | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | 3-UTRSNV | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | 3-UTRSNV | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | 3-UTRSNV | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | 3-UTRSNV | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | 3-UTRSNV | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | 3-UTRSNV | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| AKT3 | intron_variant), AKT3 MUT* (intron_variant | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| KMT2A | 3-UTRSNV), MLL MUT* (intron_variant | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | 3-UTRSNV), MLL MUT* (intron_variant | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | 3-UTRSNV), MLL MUT* (intron_variant | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | 3-UTRSNV), MLL MUT* (intron_variant | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | 3-UTRSNV), MLL MUT* (intron_variant | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | 3-UTRSNV), MLL MUT* (intron_variant | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| NOTCH1 | intron_variant | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | intron_variant | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRAF | splice_donor_variant | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | splice_donor_variant | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | splice_donor_variant | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | splice_donor_variant | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| FGFR3 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| NOTCH1 | intron_variant), NOTCH1 MUT* (intron_variant | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | intron_variant), NOTCH1 MUT* (intron_variant | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| RAF1 | intron_variant | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | intron_variant | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | intron_variant | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| CTNNB1 | S37C | Complete Match | Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) | Responsive | ED | Early trials |
| CTNNB1 | S37C | Complete Match | Tankyrase inhibitor | Resistant | COREAD | Pre-clinical |
| BRAF | intron_variant | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | intron_variant | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | intron_variant | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | intron_variant | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| KMT2A | intron_variant | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | intron_variant | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | intron_variant | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | intron_variant | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | intron_variant | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | intron_variant | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NRG1 | 5-UTRSNV | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | 5-UTRSNV | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| RET | G601E), RET MUT* (V427L | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | G601E), RET MUT* (V427L | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | G601E), RET MUT* (V427L | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | G601E), RET MUT* (V427L | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | G601E), RET MUT* (V427L | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | G601E), RET MUT* (V427L | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | G601E), RET MUT* (V427L | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | G601E), RET MUT* (V427L | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | G601E), RET MUT* (V427L | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| BCOR | S373* | Complete Match | Enzastaurin (PKCb inhibitor) | Responsive | ST | Pre-clinical |
| ESR1 | intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), E | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| AKT3 | intron_variant), AKT3 MUT* (intron_variant), AKT3 MUT* (intron_variant | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | R248Q | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R248Q | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R248Q | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R248Q | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R248Q | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R248Q | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R248Q | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R248Q | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R248Q | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248Q | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R248Q | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248Q | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRAF | D594G | Different Mutation | Dasatinib (BCR-ABL inhibitor) | Responsive | LUAD | Pre-clinical |
| BRAF | D594G | Different Mutation | Vemurafenib (BRAF inhibitor) | Responsive | HISEC, HISLC, NSCLC | NCCN guidelines |
| BRAF | D594G | Different Mutation | Vemurafenib (BRAF inhibitor) | Responsive | CM | NCCN guidelines |
| BRAF | D594G | Different Mutation | Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) | Responsive | CM | FDA guidelines |
| BRAF | D594G | Different Mutation | Trametinib (MEK inhibitor) | Responsive | CM | FDA guidelines |
| BRAF | D594G | Different Mutation | Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) | Responsive | CM | FDA guidelines |
| BRAF | D594G | Different Mutation | Pan-RAF inhibitor | Responsive | CANCER | Pre-clinical |
| BRAF | D594G | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CANCER | Pre-clinical |
| BRAF | D594G | Different Mutation | ERK inhibitor | Responsive | HNSC, BT | Case report |
| BRAF | D594G | Different Mutation | EGFR TK inhibitor | Resistant | LUAD | Case report |
| BRAF | D594G | Different Mutation | MEK inhibitor | Responsive | CM | Case report |
| BRAF | D594G | Different Mutation | Dabrafenib (BRAF inhibitor) | Responsive | CM | Early trials |
| BRAF | D594G | Different Mutation | BRAF inhibitor | Responsive | CM | Case report |
| BRAF | D594G | Complete Match | Sorafenib (Pan-TK inhibitor) | Responsive | CM | Pre-clinical |
| BRAF | D594G | Different Mutation | Vemurafenib (BRAF inhibitor) | No Responsive | COREAD | Early trials |
| BRAF | D594G | Different Mutation | MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) | Responsive | COREAD | Early trials |
| BRAF | D594G | Different Mutation | Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) | Responsive | COREAD | NCCN guidelines |
| BRAF | D594G | Different Mutation | Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) | Responsive | COREAD | Early trials |
| BRAF | D594G | Different Mutation | BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor | Responsive | COREAD | Early trials |
| BRAF | D594G | Different Mutation | BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor | Responsive | COREAD | Early trials |
| BRAF | D594G | Different Mutation | Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) | Responsive | COREAD | Early trials |
| BRAF | D594G | Different Mutation | Vemurafenib (BRAF inhibitor) | Responsive | MA | Early trials |
| BRAF | D594G | Different Mutation | BRAF inhibitor;MEK inhibitor | Responsive | TH | Early trials |
| BRAF | D594G | Different Mutation | BRAF inhibitor;HSP90 inhibitor | Responsive | CM | Pre-clinical |
| BRAF | D594G | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| BRAF | D594G | Different Mutation | Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) | Responsive | COREAD | Early trials |
| BRAF | D594G | Different Mutation | Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) | Responsive | LUAD | FDA guidelines |
| BRAF | D594G | Different Mutation | Dabrafenib (BRAF inhibitor) | Responsive | NSCLC | NCCN guidelines |
| BRAF | D594G | Different Mutation | MEK inhibitor | Responsive | TH | Early trials |
| BRAF | D594G | Different Mutation | BRAF inhibitor;PI3K pathway inhibitor | Responsive | CM | Pre-clinical |
| BRAF | D594G | Different Mutation | Dabrafenib (BRAF inhibitor) | Responsive | LUAD, TH | Early trials |
| BRAF | D594G | Different Mutation | MEK inhibitor | Responsive | OV | Pre-clinical |
| BRAF | D594G | Different Mutation | Vemurafenib (BRAF inhibitor) | Responsive | CM | FDA guidelines |
| BRAF | D594G | Different Mutation | Vemurafenib (BRAF inhibitor) | Responsive | HCL, LUAD, MYMA | Case report |
| BRAF | D594G | Different Mutation | Pan-RAF inhibitor | Responsive | CM | Early trials |
| BRAF | D594G | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| BRAF | D594G | Different Mutation | BRAF inhibitor | Responsive | G | Pre-clinical |
| BRAF | D594G | Different Mutation | BRAF inhibitor;CDK2/4 inhibitor | Responsive | CM | Pre-clinical |
| BRAF | D594G | Different Mutation | PLX4720 (BRAF inhibitor) | Responsive | MA | Pre-clinical |
| BRAF | D594G | Different Mutation | Vemurafenib (BRAF inhibitor) | Responsive | THCA | Early trials |
| BRAF | D594G | Different Mutation | Selumetinib (MEK inhibitor) | Responsive | PG | Early trials |
| BRAF | D594G | Different Mutation | ERK inhibitor | Responsive | LUAD | Early trials |
| BRAF | D594G | Different Mutation | ERK inhibitor | Responsive | CM | Pre-clinical |
| BRAF | D594G | Different Mutation | Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) | Responsive | NEU | Case report |
| BRAF | D594G | Different Mutation | BRAF inhibitor | Responsive | OV | Case report |
| BRAF | D594G | Different Mutation | Dabrafenib (BRAF inhibitor) | Responsive | GIST | Case report |
| BRAF | D594G | Different Mutation | Dabrafenib (BRAF inhibitor) | Responsive | CM | FDA guidelines |
| BRAF | D594G | Different Mutation | Dasatinib (BCR-ABL inhibitor) | Responsive | LUAD | Case report |
| BRAF | D594G | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | D594G | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | D594G | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | D594G | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| TSC1 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | BLCA | Early trials |
| TSC1 | splice_acceptor_variant | Complete Match | MTOR inhibitor | Responsive | RA | Early trials |
| TSC1 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | RA | FDA guidelines |
| TSC1 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | ST, S | Case report |
| TSC1 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | R | Case report |
| TSC1 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | GCA | FDA guidelines |
| TSC1 | splice_acceptor_variant | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | R | Case report |
| ESR1 | intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| BCR | intron_variant), BCR MUT* (intron_variant | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | intron_variant), BCR MUT* (intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | intron_variant), BCR MUT* (intron_variant | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | intron_variant), BCR MUT* (intron_variant | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | intron_variant), BCR MUT* (intron_variant | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | intron_variant), BCR MUT* (intron_variant | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| NTRK1 | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | intron_variant | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | intron_variant | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | intron_variant | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| Variation | Gene | Transcript | Protein Alteration | Consequence | Tumour Driver | Oncogenic Classification |
|---|
Drug-Gene Interactions help
Druggable categories in the cohort
Focus the search to a gene of interest:
Loading...
| Gene | Interaction Source | Interaction Types | Drug Claim Primary Name | Drug Name | ChEMBL ID |
|---|
Phenotype
Protein
Drug
Principal Component Analysis
PCA Help
Scatterplot of Two main Principal Components
Click on legend to highlight trace
Scatterplot of Three main Principal Components
Gene Expression
Correlation
Survival Analysis
There are Blood (Plasma, Serum, Buffy coat), FFPE tissue, Fresh frozen tissue samples from unique donors available at PCRFTB, based on the selected clinical filters (Age, Sex, Race, Diagnosis). Researchers can request for samples by submitting an Expression of Interest to PCRFTB.
Overview
Sex
Race
Diagnosis
Tumor stage
Age at Diagnosis